TD2 RECENT HEADLINES

TD2 is the development partner for the FORMA/Celgene partnership

TD2 is the development partner for the FORMA/Celgene partnership

WATERTOWN, Mass. – April 29, 2013 – FORMA Therapeutics Holdings, LLC (FORMA) today announced a str...

Forma Therapeutics teams with TD2

FORMA Therapeutics and Translational Drug Development (TD2) today announced an agreement to jointly develop transformative cancer therapies, leveraging the synergistic capabilities of both o...

Flagship Biosciences finds Arizona a great home for serving pathology digitally

"...While most of Flagship’s customers are at biotech and pharma locations around the world, there has been some strong collaborations formed with Arizona biotech firms. “Th...

CytRx Initiates Phase 2 Clinical Trial with INNO-206 in Pancreatic Cancer

"...Daniel Von Hoff, M.D., Physician-in-Chief and Distinguished Professor at the Translational Genomics Research Institute (TGEN) in Phoenix will serve as the clinical trial’s pri...

TGen Drug Development (TD2) partnership with Imaging Endpoints provides comprehensive clinical trial services for drug developers

TGen Drug Development (TD2) and Imaging Endpoints have teamed up to enable the rapid development of anti-cancer drugs and deliver them faster to patients in need, the companies announced tod...

Avantra Biosciences

Avantra Biosciences teams with TGen Drug Development to assist pharma